What Matters Most for Long-Acting Antiretroviral Therapy? [...] A Discrete Choice Experiment Presented by: Rebecca Fisk-Hoffman, MPHFunding • Supported by the National Institute on Alcohol Abuse and Alcoholism (F31AA030518, U24AA022002), the National Institute of Allergy and Infectious Disease (R01AI172875), and Merck’s Investigator-Initiated ProgramBackground • Alternative to daily pills needed and many options in development – Unknown what PWH may pref
- Pages
- 16
- Published in
- United States of America
